You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
Latest News
May 21, 2020 — ADMA Biologics Commences Collection of COVID-19 Plasma from Recovered Patients
Groundbreaking Immunotechnology, One Connection at a Time.
ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection. Our devotion to these underserved populations fuels us, and our hands-on approach to production and development sets us apart.
View Our Latest Corporate Presentation
Poised for Growth
Beyond our present focus on the clinical advancement of ASCENIV™ and the expansion of our plasma facilities, we are considering a number of additional opportunities for growth:
- Evaluating strategies for potential manufacturing capacity expansion.
- Exploring additional clinical research and commercial opportunities to address unmet needs for immunocompromised patients.
- Developing additional plasma-derived products through direct R&D and potential licensing opportunities. These follow-on products may include infectious disease specific intravenous immune globulin (IVIG) product candidates targeting immunocompromised patients as well as transplant patients.
- ADMA Biologics offers a full suite of CDMO and CMO partnering opportunities.
Fiscal Year 2019 Report
Download ReportOur Diversity Makes Us Stronger
The members of ADMA Biologics' management team come from different disciplines and professional backgrounds, we share a common passion and desire to drive goals that improve the lives of patients.
Meet the ADMA Team